Sigma-Aldrich signs exclusive distribution agreement with Roche

Published: 19-Mar-2015
Ingredients

Provides researchers with global access to Roche biochemical reagents


Sigma-Aldrich has agreed, in an exclusive deal, to distribute Roche's Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR (polymerase chain reaction) applications.

Eric Green, Executive Vice President and President, Sigma-Aldrich Research, said the addition of these life science tools 'supports our strategy to augment our portfolio with products that accelerate customer scientific research programmes'.

Transfer of the Roche portfolio to Sigma-Aldrich will take place during 2015. In the interim, these products will continue to be available through existing Roche channels.

  • Companies:
  • Roche Group
  • Merck Electronics KGaA
See more

You may also like

Ingredients

Therapeutic: crovalimab for paroxysmal nocturnal haemoglobinuria

Read more
Paroxysmal nocturnal haemoglobinuria (PNH) is an inherited blood disorder wherein anaemia results from the destruction of red blood cells by the complement system

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. A new solvent for green chemistry Cyclopentyl methyl ether has properties that make it easy to use, greener, and a more cost effective process solvent for many types of synthesis. Zeon Corporation explains why
  3. Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
  4. Logical Biological expands its raw pharma material development and supply capabilities with new lab The raw material supplier can now better serve in vitro diagnostic (IVD) manufacturers, as it has a significantly larger operational capacity
  5. The modularisation of chemical API synthesis The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Ingredients

Therapeutic: crovalimab for paroxysmal nocturnal haemoglobinuria

Paroxysmal nocturnal haemoglobinuria (PNH) is an inherited blood disorder wherein anaemia results from the destruction of red blood cells by the complement system
Ingredients

Merck expands granulated excipient line for pharma products

The company has launched a multi-compendial excipient with broad application in both pharma and biopharma
Manufacturing

MilliporeSigma adds full viral vector contract services with new platform

This new launch has made it one of the first CDMOs and technology developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development
Manufacturing

Merck opens $63m CDMO facility to handle HPAPIs

The industry expert has announced that its Life Science business sector has doubled its highly potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of this facility
Ingredients

Therapeutics: tepotinib for lung cancer

Lung cancer is the most common type of cancer, with an estimated 2 million cases being diagnosed every year and 1.7 million deaths recorded
Ingredients

Managing the unavoidable: A practical approach to handling TUPs

Technically unavoidable particles (TUPs) are found in chemical raw materials, such as excipients. They do not pose a risk to patient safety, but can create problems if not managed well. Merck KGaA's Dr Torsten Schadendorf and Jennifer Standare explain
Ingredients

Merck makes nanoparticle-reduced sucrose with new filtration process

The product is based on a new filtration-based manufacturing process for reduced levels of nanoparticle impurities in biopharmaceutical formulations
Subscribe now